# Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer

> **NCT04754425** · PHASE2 · TERMINATED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 11 (actual)

## Conditions studied

- Castration-Resistant Prostate Carcinoma
- Castration-Resistant Prostate Carcinoma Refractory to Second-Generation Androgen Receptor Axis-Targeted Agents
- Metastatic Malignant Neoplasm in the Bone
- Metastatic Prostate Adenocarcinoma
- Metastatic Prostate Small Cell Neuroendocrine Carcinoma
- Stage IV Prostate Cancer AJCC v8
- Stage IVA Prostate Cancer AJCC v8
- Stage IVB Prostate Cancer AJCC v8

## Interventions

- **PROCEDURE:** Biopsy
- **PROCEDURE:** Biospecimen Collection
- **DRUG:** Erdafitinib

## Key facts

- **NCT ID:** NCT04754425
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-07-15
- **Primary completion:** 2026-02-02
- **Final completion:** 2026-02-02
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** \<75% participation
- **Last updated:** 2026-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04754425

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04754425, "Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04754425. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*